



1646
1FW

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Washington, DC 22313-1450, on the date shown below.

Dated: June 30, 2005

Signature: 

Katherine L. Neville

Docket No.: 01017/36667
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Banks, W.

Application No.: 10/049,182

Group Art Unit: 1646

Filed: June 19, 2002

Examiner: Kolker, D.

For: Modulation of the Blood-Brain Barrier
Transporter for Leptin

RESPONSE PURSUANT TO 37 CFR §1.11

MS Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Dear Sir:

This paper is filed in response to an Office Action (hereinafter "the Action"), mailed March 31, 2005 in the above-referenced application, wherein pending claims 1-5 were variously rejected under 35 U.S.C. §112, first paragraph, for assertedly lacking written description and enablement, under 35 U.S.C. § 102(b) as assertedly anticipated by Gamaro et al., (*Neurobiology of Learning and Memory* 68:221-29, 1997.) (hereinafter "Gamaro"), under 35 U.S.C. § 102(a) as assertedly anticipated by Mostyn et al., (*Proceedings of the Nutrition Society* 58:69A, 1998) (hereinafter "Mostyn"), and under 35 U.S.C. § 103(a) as assertedly obvious in view of Gamaro, further in view of Bigsby, US Patent 3,074,847 (hereinafter "Bigsby"), and Banks et al. (*Peptides*, 17:305-11, 1996) (hereinafter "Banks"). Reconsideration is requested in light of the following amendments and remarks.

This response is due on June 30, 2005 without resort to the provisions of 37 C.F.R.

§1.136.

Amendments to the claims are reflected in the claims set beginning on page 3 of this paper.

Remarks begin on page 11 of this paper.